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ABSTRACT 7 
Background. Bulimia nervosa is a severe eating disorder that can be managed using a 8 
variety of treatments including pharmacological, psychological, and combination treatments. 9 
We aimed to compare their effectiveness and to identify the most effective for the treatment 10 
of bulimia nervosa in adults. 11 
Methods. A search was conducted in Embase, Medline, PsycINFO and Central from their 12 
inception to July 2016. Studies were included if they reported on treatments for adults who 13 
fulfilled diagnostic criteria for bulimia nervosa. Only RCTs that examined available 14 
psychological, pharmacological, or combination therapies licensed in the UK were included. 15 
We conducted a network meta-analysis (NMA) of RCTs. The outcome analysed was full 16 
remission at the end of treatment.  17 
Results. We identified 21 eligible trials with 1,828 participants involving 12 treatments, 18 
including wait list. The results of the NMA suggested that individual CBT (specific to eating 19 
disorders) was most effective in achieving remission at the end of treatment compared with 20 
wait list (OR 3.89, 95% CrI 1.19 to 14.02), followed by guided cognitive behavioural self-help 21 
(OR 3.81, 95% CrI 1.51 to 10.90). Inconsistency checks did not identify any significant 22 
inconsistency between the direct and indirect evidence. 23 
Conclusions. The analysis suggested that the treatments that are most likely to achieve full 24 
remission are individual CBT (specific to eating disorders) and guided cognitive behavioural 25 
self-help, although no firm conclusions could be drawn due to the limited evidence base. 26 
There is a need for further research on the maintenance of treatment effects and the 27 
mediators of treatment outcome. 28 
Key words: eating disorder, bulimia nervosa, network meta-analysis, outcome research, 29 
National Institute of Health and Care Excellence. 30 
Word count: 248 (abstract); 3,745 (main paper) 31 
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INTRODUCTION 32 
Bulimia nervosa (BN) is an eating disorder with an estimated lifetime prevalence of 1-3% 33 
(Trace et al. 2012; Smink et al. 2013; Stice et al. 2013). It is characterised by recurrent binge 34 
eating, extreme weight-control behaviour and an overconcern about body shape and weight 35 
(Cooper and Fairburn, 1993; Fairburn and Harrison, 2003) and generally starts in late 36 
adolescence or early adulthood. Although it usually begins with strict dieting and some 37 
weight loss, this dietary restriction becomes punctuated after some months or years by 38 
repeated binges and weight regain. In most cases, people with BN engage in purging and 39 
compensatory behaviours that include the use of excessive exercise and/or dietary 40 
restriction. 41 
Cognitive behavioural therapy specific to eating disorders (CBT-ED) has been demonstrated 42 
to be an effective approach for the treatment of BN (Hay, 2013; Poulsen et al. 2014; Fairburn 43 
et al. 2015; Linardon et al. 2017). Some evidence suggests that interpersonal psychotherapy 44 
(IPT) can achieve results similar to CBT, although it is much slower to achieve these effects 45 
(Fairburn et al. 1993; Agras et al. 2000). The more recent µenhanced¶ form of CBT appears 46 
to be more effective than IPT even at follow-up (Fairburn et al. 2015). There is also evidence 47 
that supports the use of guided cognitive behavioural self-help (Bailer et al. 2004; Wagner et 48 
al. 2013). There are many more treatments for BN, although data on their outcomes are 49 
limited to date.  50 
Traditional pairwise meta-analyses of RCTs are used to synthesize the results of different 51 
trials comparing the same pair of treatments, to obtain an overall estimate of the effect of 52 
one treatment relative to another. However, the few extant meta-analyses of treatments for 53 
people with BN have been limited to comparisons of a narrow range of treatments (Whittal et 54 
al. 2000; Thompson-Brenner et al. 2003; Hay, 2013; Polnay et al. 2014; Linardon et al. 55 
2017). Network meta-analysis (NMA) has advantages over standard pairwise meta-analysis 56 
in that (1) all the treatments that have been tested in RCTs can be simultaneously compared 57 
to each other in one analysis; and (2) their effects can be estimated relative to each other 58 
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and to a common reference condition (such as a wait list). Estimates of the relative effects of 59 
pairs of treatments that have often, rarely, or never been directly compared in an RCT can 60 
be calculated. Consequently, an NMA overcomes some of the limitations of a traditional 61 
meta-analysis in which conclusions are largely restricted to comparisons between treatments 62 
that have been directly compared in RCTs (Dias et al. 2013). 63 
An NMA was developed and conducted of all psychological, pharmacological, and 64 
combination therapies that are used for the treatment of adult BN, and which have been 65 
tested in RCTs. This NMA was used to inform the new national clinical guidance for eating 66 
disorders in England released by the National Institute for Health and Care Excellence 67 
(NICE, 2017). The guideline was developed by a Guideline Committee, an independent 68 
multi-disciplinary team consisting of clinical academics, health professionals and service 69 
users and carer representatives with expertise and experience in the field of eating 70 
disorders. This article reports the findings of the NMA that was conducted to inform the NICE 71 
guideline on the most effective treatments for BN in adults. 72 
73 
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METHODS 74 
Search strategy 75 
A search for published and unpublished studies on the treatment of adults with eating 76 
disorders was conducted in the databases Embase, Medline, PsycINFO and Central to 77 
inform the NICE guideline. All databases were searched from their inception to July 2016 78 
and no language limits were set. The strategy used terms covering all eating disorders, in 79 
accordance with the NICE guideline scope. The balance between sensitivity (the power to 80 
identify all studies on a particular topic) and specificity (the ability to exclude irrelevant 81 
studies from the results) was carefully considered, and a decision was made to utilise a 82 
broad, population-based approach to the search in order to maximise retrieval in a wide 83 
UDQJHRIDUHDV7RDLGUHWULHYDORIUHOHYDQWDQGVRXQGVWXGLHVµILOWHUV¶ZHUHXVHGZKHUH84 
appropriate) to limit the search results to RCTs. See Supplementary Appendix 1 for full 85 
details of the search terms used. 86 
Selection criteria 87 
A systematic review of interventions for BN was carried out according to Preferred Reporting 88 
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009).  89 
The titles and abstracts of identified studies were screened by two reviewers against 90 
inclusion criteria specified in the guideline review protocols, until a good inter-rater reliability 91 
ZDVREVHUYHGSHUFHQWDJHDJUHHPHQW, or Kappa statistic K>0.60) (NICE, 2017). Any 92 
disagreements between raters were resolved through discussion. Once full versions of the 93 
selected studies were acquired for assessment, full studies were checked independently by 94 
two reviewers, with any differences being resolved with discussion. Data were extracted on 95 
the study characteristics, aspects of the methodological quality, outcome data, and risk of 96 
bias. 97 
RCTs for the systematic review of treatments for BN were included if they reported on 98 
treatments for people aged at least 18 years who fulfilled diagnostic criteria for BN (i.e. DSM-99 
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IV). Two reviewers independently assessed eligibility: studies were included if they were 100 
RCTs examining psychological, pharmacological, or combination therapies compared with a 101 
wait list, pill placebo, or another active treatment. Nutritional management was not 102 
considered in the review as this was seen as an add on to treatments for people with BN. 103 
Also, only treatments available and licensed in the UK for BN were included.  104 
According to the NICE Guideline Committee¶VH[SHUW view, it was important to differentiate 105 
between CBT-specific to eating disorders (CBT-ED) and generic CBT. CBT-ED is the 106 
leading form of treatment for BN that places emphasis on the eating disorder 107 
psychopathology and may have some differences in efficacy when compared with CBT non-108 
specific to eating disorders. It was also considered important to distinguish between group 109 
and individual treatments, and between pure and guided cognitive behavioural self-help 110 
because there may be some differences in efficacy and also on cost effectiveness, which is 111 
an important factor when making recommendations for NICE guidelines. 112 
Network meta-analysis 113 
To take all trial information into consideration, network meta-analytic techniques (mixed 114 
treatment comparisons) were employed to synthesise evidence. The critical outcomes in the 115 
systematic review conducted for the NICE guideline were remission, long-term recovery, and 116 
binge eating. The guideline systematic review of the clinical literature identified only one 117 
dichotomous outcome that could be utilised in the NMA - full remission at the end of 118 
treatment ± as the reporting of the other outcome measures was inconsistent across the 119 
trials. The NMA was also used to inform a cost-effectiveness analysis and the Guideline 120 
Committee was of the view that full remission at the end of treatment was an important 121 
outcome to pursue in the economic evaluation. 122 
The identified RCTs employed a range of definitions of full remission, utilising criteria such 123 
as abstinence from binge eating and purging. Following consultation with the NICE Guideline 124 
Committee, RCTs were included only if they defined full remission as either the abstinence 125 
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of bulimia-related symptoms over a minimum of a two week period, or as no longer meeting 126 
DSM-IV criteria for BN (including cognitive elements). The definition of remission was 127 
decided before selection of studies. A number of excluded studies employed shorter time 128 
frames or lesser symptom reduction. However, stricter criteria for defining full remission were 129 
used because the fluctuating nature of symptom severity and gaps between behaviours in 130 
BN mean that a shorter time period would not be clinically meaningful. In studies where the 131 
time frame for remission was unclear, the Guideline Committee was consulted to decide 132 
whether the study should be included in the review.  133 
A network of treatments included in the systematic review, for which data on full remission at 134 
end of treatment were available, was designed. Only treatments that were connected to the 135 
network were considered. Treatment-as-usual arms were excluded, since the definitions of 136 
µtreatment-as-usual¶ varied across the studies and were therefore not informative to the 137 
Guideline Committee. Head-to-head comparisons of no interest (such as interventions not 138 
available or licensed for BN in the UK, as well as controls of no interest) were excluded from 139 
the analysis unless they allowed indirect comparisons between interventions of interest (see 140 
Supplementary Appendix 2 for details of the included studies in the NMA). An intention to 141 
treat (ITT) analysis was adopted when estimating full remission (that is, all randomised 142 
patients were included and anyone discontinuing treatment, for whatever reason, was 143 
assumed not to be in remission). The flowchart diagram for the NMA is provided in Figure 1. 144 
Insert Figure 1 145 
The Committee made an a priori assumption that there would need to be at least 200 people 146 
randomised to a treatment across all included trials in the NMA for them to make a 147 
recommendation with confidence.  148 
Statistical analysis 149 
Both fixed effects and random effects models (Binomial Likelihood and Logit link) were run 150 
(see the Supplementary Appendix 3 and 4 for WinBUGS fixed effects and random effects 151 
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model codes, respectively) (Dias et al. 2011A). The goodness-of-fit of each model to the 152 
data was measured by comparing the posterior mean of the summed deviance contributions 153 
to the number of data points (Dempster, 1997). The Deviance Information Criterion (DIC), 154 
which is equal to the sum of the posterior mean of the residual deviance and the effective 155 
number of parameters, was used as the basis for model comparison (Spiegelhalter et al. 156 
2002). Model selection was also influenced by the posterior mean between study 157 
heterogeneity standard deviation (SD). Analyses were undertaken in a Bayesian framework, 158 
using WinBUGS 4.1.3 (Lunn et al. 2013). 159 
Relative effects are reported as odds ratios with 95% credible intervals (CrI). Treatments 160 
were also ranked based on their effectiveness, with lower ranks indicating more effective 161 
treatments. Median ranks and 95% CrI are presented for each treatment. 162 
Continuity correction 163 
In the dataset, several studies reported zero events of interest in some arms (that is, the 164 
number of people achieving full remission was zero). Combining such data can be 165 
problematic: when zero events occur in some arms of a study, the log-odds ratio becomes 166 
undefined (as does the variance), which causes problems in the analysis and precludes the 167 
estimation of relative effects. As a result, continuity corrections are needed. Using a 168 
continuity correction for studies with zero counts allows the log-odds ratio to be estimated, 169 
and hence allows synthesis via standard NMA methods. There are many possible continuity 170 
correction methods (Sweeting et al. 2004). In the present study, a continuity correction of 0.5 171 
was added to both the number of events and the number of non-events across all study 172 
arms, in studies in which one or more (but not all) arms had zero events. 173 
Inconsistency checks 174 
A basic assumption of an NMA is that direct and indirect evidence estimate the same 175 
parameter. That is, the relative effect between A and B measured directly from an A versus 176 
B trial is the same as the relative effect between A and B estimated indirectly from A versus 177 
C and B versus C trials. Inconsistency arises when there is a conflict between direct 178 
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evidence (from an A versus B trial) and indirect evidence (gained from A versus C and B 179 
versus C trials). This consistency assumption has also been termed the similarity or 180 
transitivity assumption (Mavridis et al. 2015). 181 
Evidence of inconsistency was checked for by comparing the standard network consistency 182 
model to an µinconsistency¶, or unrelated mean effects, model (Dias et al. 2013). The latter is 183 
equivalent to having separate, unrelated meta-analyses for every pair-wise contrast but with 184 
a common variance parameter in random effects models. Improvement in model fit or a 185 
substantial reduction in heterogeneity in the inconsistency model compared to the NMA 186 
consistency model, indicates evidence of inconsistency. The WinBUGS code for the 187 
inconsistency model is provided in the Supplementary Appendix 5 (Dias et al. 2011B). 188 
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RESULTS 189 
Identified studies and treatments 190 
Seventy-five potentially eligible studies were identified, 54 of which were excluded (Figure 191 
1). Twenty-one trials with 1,828 participants provided direct or indirect evidence on full 192 
remission associated with 12 treatment options: wait list, individual CBT-ED, individual 193 
interpersonal psychotherapy (IPT), guided cognitive behavioural self-help, individual 194 
behaviour therapy (BT), pure cognitive behavioural self-help (i.e., self-help with no support), 195 
group CBT-ED group, fluoxetine, relaxation, individual CBT-ED plus fluoxetine, group BT, 196 
and supportive psychotherapy. Among the 21 trials there were 6 studies (N = 452) 197 
comparing the same treatment in both arms (e.g. CBT-ED vs. CBT-ED, etc.). Nevertheless, 198 
these were retained in the NMA as they contributed to the estimation of between-study 199 
heterogeneity. The resulting network of trials contributing data to the NMA is presented in 200 
Figure 2. (Full details of the excluded studies are provided in the Supplementary Appendix 6 201 
and the final data file used in the NMA is shown in Supplementary Appendix 7.) 202 
Insert Figure 2 203 
Risk of bias assessment 204 
All included trials were assessed for risk of bias using the GRADE risk of bias tool (Balshem 205 
et al. 2011; Guyatt et al. 2011). Sequence generation and allocation concealment were 206 
adequately described in eleven and three trials, respectively. Trials were regarded at high 207 
risk of bias for lack of participant and provider masking. In four studies, assessors were 208 
aware of treatment assignment, and in four trials it was unclear if the assessors were 209 
blinded. Attrition was high in most trials. However, we used ITT analysis and treated drop 210 
outs as failures. As a result, attrition bias was not considered in the assessment. Included 211 
trials reported a variety of outcomes. Only two trials were registered on a trials database. 212 
Consequently, most studies were judged as being at unclear risk of reporting bias. No other 213 
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potential biases were identified. (Risk of bias tables are presented in the Supplementary 214 
Appendix 8.) 215 
NMA model fit statistics 216 
Convergence was satisfactory after at least 70,000 iterations. Models were then run for a 217 
further 70,000 iterations on two separate chains, and results are based on this further 218 
sample. The fixed and random effects models had a similar fit to the data when comparing 219 
the posterior mean residual deviance and DIC values. Moderate to high between-trials 220 
KHWHURJHQHLW\ZDVREVHUYHGZKHQDUDQGRPHIIHFWVPRGHOZDVXVHGĲ &U, 221 
to 0.93), which was of a similar magnitude to the relative effects expressed on the log-odds 222 
ratio scale (see Supplementary Appendix 9). No substantial differences were observed in 223 
posterior mean residual deviance or DIC values compared to the inconsistency model, which 224 
suggests no inconsistency. Model fit statistics for the fixed and random-effects models, 225 
continuity corrected, and for the random-effects inconsistency model are provided in 226 
Supplementary Appendix 10. The random effects model had a slightly more favourable fit 227 
than the fixed effects, therefore all further analyses are based on that model.  228 
Treatment outcomes 229 
The posterior median odds ratios (OR) and 95% CrI for each treatment for achieving full 230 
remission at the end of treatment compared to every other treatment are reported in Table 1. 231 
Compared with wait list, individual CBT-ED (OR 3.89, 95% CrI 1.19 to 14.02), guided 232 
cognitive behavioural self-help (OR 3.81, 95% CrI 1.51 to 10.90), pure cognitive behavioural 233 
self-help (OR 3.49, 95% CrI 1.20 to 11.21), group CBT-ED (OR 7.67, 95% CrI 1.51 to 234 
55.66), and group BT (OR 28.70, 95% CrI 3.11 to 455.3) were significantly better at 235 
achieving full remission at the end of treatment. Group BT was also better than IPT, 236 
fluoxetine, individual BT, and relaxation. However, as indicated by the very wide 95% CrI, 237 
there was high uncertainty regarding the treatment effects of group BT and group CBT-ED. 238 
These therapies had very small numbers randomised across all studies and, as a result, 239 
their effects were very uncertain. Although there were differences in the mean effects 240 
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between any other treatments, these were not statistically significant. The posterior median 241 
log odds ratios (LOR) and 95% CrI for each treatment compared to every other for achieving 242 
full remission at the end of treatment as estimated by the NMA (and, where available, the 243 
respective results from the pairwise analysis) are provided in Supplementary Appendix 9. 244 
The NMA and pairwise results were in agreement in all cases, which strengthens the results 245 
of the NMA. 246 
Figure 3 shows the ORs (on a log-scale) in remission compared to wait list. Most of the 247 
treatments had very wide CrI and crossed the line of no effect. Most CrI also overlapped, 248 
indicating no difference between the treatments. 249 
Insert Table 1 250 
Insert Figure 3 251 
Treatment rankings  252 
The treatments with the lowest posterior median rank were group BT (1st, 95% CrI 1st to 5th), 253 
followed by group CBT-ED (3rd, 95% CrI 1st to 9th), individual CBT-ED (4th, 95% CrI 2nd to 7th), 254 
and guided cognitive behavioural self-help (5th, 95% CrI 2nd to 8th). Table 2 shows the 255 
posterior median ranks and the associated 95% CrI.  256 
Insert Table 2 257 
The full results of the NMA are provided in Supplementary Appendix 11.  258 
259
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DISCUSSION 260 
To our knowledge, this is the first reported NMA in people with BN. Only one previous NMA 261 
in people with eating disorders was identified, examining the effectiveness of psychological 262 
and pharmacological interventions for binge-eating disorder (Peat et al. 2017). Overall, the 263 
results of the present NMA suggest that group BT, group CBT-ED, individual CBT-ED and 264 
guided cognitive behavioural self-help are more effective than other treatments in achieving 265 
full remission at the end of treatment. The findings for group BT and group CBT-ED were 266 
based on very small numbers randomised (N < 70), and were characterised by very wide 267 
CrI. Similarly, the evidence for other treatments, with the exception of IPT, was limited. 268 
However, the mean effects for these treatments suggest a less good outcome when 269 
compared with cognitive or behavioural therapies. As a result, individual CBT-ED and guided 270 
cognitive behavioural self-help are the treatments for which there is the most reliable 271 
evidence. Also, the inconsistency checks did not identify any significant inconsistency 272 
between the direct and indirect evidence included in the NMA, which strengthens the 273 
conclusions of the analysis.  274 
Not all trials identified in the systematic review provided data on full remission. µFull 275 
remission¶ was not clearly defined in some RCTs, and there was wide variation in its 276 
definition when it was reported. In particular, a number of RCTs were excluded because 277 
remission was defined as abstinence from bulimia-related symptoms over a period of less 278 
than 2 weeks. According to the NICE Guideline Committee¶V expert opinion only abstinence 279 
from bingeing over and above two weeks should be considered. Although this two-week 280 
period was seen as a relatively weak definition, more stringent inclusion criteria would have 281 
excluded the majority of studies since only few of them had longer reported periods.  282 
It is acknowledged that not meeting full DSM-IV criteria is not the same as abstinence from 283 
binge eating and compensatory behaviours, and it could potentially include people in partial 284 
remission. However, given a limited evidence base the committee made a decision to 285 
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include such studies. Use of the DSM-V criteria would have been more inclusive but DSM-IV 286 
criteria was still in operation when nearly all of the studies were conducted. 287 
It should also be noted that papers used inconsistent definitions of behaviour change. Future 288 
research needs to adopt consistent and rigorous definitions. It is proposed that µabstinence¶ 289 
be defined as (1) no objective binges or purging behaviours over the previous three months 290 
and (2) being not underweight. Similarly, µfull remission¶ should be defined as abstinence, 291 
plus attitudes towards eating, weight and shape within one standard deviation of the 292 
community range for the relevant population. 293 
The ITT analysis meant that all participants were analysed in the group to which they had 294 
been randomized and all study non-completers were assumed to not be in remission. This 295 
strategy was supported by the NICE guideline committee and provides a conservative 296 
estimate of treatment effects. 297 
It was not possible to investigate whether the end of treatment effects persisted or 298 
diminished in the long term because most trials stopped at the end of treatment (usually at 299 
16 weeks). Hence, there was insufficient evidence to inform an NMA using remission data at 300 
long-term follow-up. Also, even though we included only those treatments available and 301 
licensed for use in the UK, only one trial was excluded on the grounds of being of no interest 302 
(Pope et al. 1989, which compared trazodone with pill placebo). The findings should 303 
therefore be of interest to an international audience.  304 
One limitation of the study is that the literature search is over a year old. However, a 305 
literature search on PubMed (conducted March 2018) failed to identify any relevant new 306 
RCTs.  307 
The finding that, among the treatments with a robust evidence base, individual CBT-ED 308 
appears to be the most effective option to achieve remission at the end of treatment for 309 
people with BN is in line with other systematic reviews (Linardon et al. 2017; Polnay et al. 310 
2014; Hay, 2013; Shapiro et al. 2007). Our analysis suggests that guided cognitive 311 
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behavioural self-help is also effective. This outcome is also consistent with the findings of 312 
systematic reviews by Beinter et al. (2014) and Linardon et al. (2017), which showed that 313 
cognitive behavioural self-help treatments are useful in the treatment of BN (especially if the 314 
features of their delivery and indications are considered carefully).  315 
A review by Polnay et al. (2014) suggested that group CBT was effective compared with no 316 
treatment. However, there was insufficient evidence in their review on the effectiveness of 317 
group CBT relative to individual CBT. Our use of mixed treatment methodology enabled us 318 
to compare group therapies with other available treatment options. Although group CBT-ED 319 
and group BT were effective in achieving remission at the end of treatment, the estimates of 320 
effect were extremely uncertain. Similarly, even though combination therapies (e.g. CBT plus 321 
fluoxetine) and other psychological therapies (including individual IPT and individual BT) 322 
have shown some efficacy in individual studies, our synthesis pooled evidence using direct 323 
and indirect comparisons and found their effects small compared with other available 324 
treatments.  325 
The present analysis found no convincing evidence for the effectiveness of pharmacological 326 
treatments although few studies provided direct comparisons between psychological 327 
therapies and pharmacological treatments.  328 
Taking all these factors into account, the NICE guideline recommended that bulimia-329 
nervosa-focused guided self-help should be offered as the first treatment for adults with BN 330 
in a stepped care treatment strategy, with the second step being individual eating-disorder-331 
focused cognitive behavioural therapy (CBT-ED) (NICE, 2017).  332 
Overall the evidence base was limited, in particular for a range of treatments. There is a 333 
clear need for well-conducted head-to-head studies that examine the effectiveness of 334 
pharmacological, individual as well as group psychological, and combined pharmacological 335 
and psychological therapies compared to each other for adults with BN. In particular, long-336 
term comparative outcome data are needed.   337 
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